Anti-FGFR3 antibody and use thereof

AU2026220176A1Pending Publication Date: 2026-09-10AIMED BIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
AU2026220176
Authority / Receiving Office
AU · AU
Patent Type
Applications
Current Assignee / Owner
Filing Date
2026-08-18
Publication Date
2026-09-10

Smart Images

  • Figure 00000173_0000
    Figure 00000173_0000
  • Figure 00000173_0001
    Figure 00000173_0001
  • Figure 00000174_0000
    Figure 00000174_0000
Patent Text Reader

Abstract

【ABSTRACT】 The present invention relates to: an anti-fibroblast growth factor receptor 3 (FGFR3) antibody or antigen- binding fragment thereof; a nucleic acid encoding same; a recombinant expression vector comprising the nucleic acid; a host cell transfected with the recombinant expression vector; a method for producing the antibody or antigen- binding fragment thereof; a bispecific or multispecific antibody comprising the antibody or antigen-binding fragment thereof; an immune cell-engaging bispecific or multispecific antibody comprising an scFv including an scFv of the antibody and a second binding domain comprising at least one scFv of an antibody that binds to an immune cell- activating antigen; an antibody-drug conjugate (ADC) in which the antibody or the antigen-binding fragment thereof is bound to a drug; a chimeric antigen receptor (CAR) comprising the scFv of the anti-FGFR3 antibody as an antigen-binding site of an extracellular domain; an immune cell having the chimeric antigen receptor introduced thereinto; a composition for combination treatment comprising the immune cell; a composition for combination treatment comprising the antibody or the antigen-binding fragment thereof; a composition for treating cancer; a method for treating cancer; and a vesicle comprising the antibody or the antigen-binding fragment thereof.
Need to check novelty before this filing date? Find Prior Art